Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
RESEARCH TOOLSreports
Holding ARTV?
Track your performance easily
ARTV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.68 - $17.31
Previous Close$10.88
Volume4.28K
Average Volume (3M)137.08K
Market Cap
$269.13M
Enterprise Value$132.48M
Total Cash (Recent Filing)$146.63M
Total Debt (Recent Filing)$14.97M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 12, 2024EPS Estimate
-$0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding24,289,328
10 Day Avg. Volume59,222
30 Day Avg. Volume137,084
Standard Deviation0.34
R-Squared0.65
Alpha-0.18
Financial Highlights & Ratios
Price to Book (P/B)1.32
Price to Sales (P/S)608.58
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue293.75
Enterprise Value/Gross Profit3.96
Enterprise Value/Ebitda-4.38
Forecast
1Y Price Target
$20.50Price Target Upside85.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Artiva Biotherapeutics, Inc. News
PremiumCompany Announcements
Artiva Biotherapeutics Reports Q3 2024 Financial Results
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $9.68 and its highest was $17.31 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Currently, no data Available
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Nov 12, 2024 which is 11 days ago.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Aug 29, 2024. The company reported -$22 earnings per share for the quarter, missing the consensus estimate of -$1.38 by -$20.62.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -$0.84.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,289,328 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$22 in its last earnings report, missing expectations of -$1.38. Following the earnings report the stock price went down -10.482%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
---
Artiva Biotherapeutics, Inc. Stock Smart Score
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
---
ARTV Stock 12 Month Forecast
Average Price Target
$20.50
▲(85.02% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering ARTV
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-2.93%
assigned a buy rating 10 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -2.93% per trade.
---